Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Cigna Q3 2026 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown, where we turn dense earnings calls into conversations you'd actually want to listen to. I'm Alex...
**JORDAN:** ...and I'm Jordan. Today we're digging into Cigna's third quarter 2026 results, and Alex, this is a company that's raising guidance while also telling investors "hey, 2027 is going to be a little weird."
**ALEX:** Exactly, lots to unpack. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Good to have that out of the way. So let's get into the numbers.
**ALEX:** Cigna posted adjusted revenue of $73.8 billion for the quarter, adjusted after-tax earnings of $2.1 billion, and adjusted EPS of $7.98. And here's the headline: they raised full-year 2026 EPS guidance to at least $30.60.
**JORDAN:** That's a nice beat-and-raise story. And it's coming from two engines — Evernorth, their health services and pharmacy arm, and Cigna Healthcare, the traditional insurance side. Evernorth revenue grew 6% to $63.8 billion, with pretax earnings of $1.8 billion. Cigna Healthcare revenue was up 9% to $11.7 billion, pretax earnings of $1.2 billion.
**ALEX:** And within Evernorth, the real star was Specialty and Care Services — that's Accredo, their specialty pharmacy, and CuraScript, their distribution business. Pretax earnings there grew 15% year-over-year to $1.1 billion.
**JORDAN:** That's being driven by biosimilars and specialty generics hitting their stride. Generic Revlimid, a big oncology drug, is now at about 90% penetration. Biosimilar Humira and Stelara are seeing strong adoption too, especially with Cigna offering zero-dollar out-of-pocket options for patients.
**ALEX:** It's a good reminder that the "boring" parts of healthcare — drug substitution, supply chain efficiency — can actually be huge profit drivers.
**JORDAN:** Right, and on the Cigna Healthcare side, their medical care ratio — basically how much premium revenue goes out the door in claims — came in at 85%, right in line with expectations. Medical customers grew 2% year-to-date to 18.5 million, with particularly strong growth in their Select segment, which serves smaller employers.
**ALEX:** Now let's talk strategy, because CEO Brian Evanko spent a lot of time on something called "Lead to 1." It's their big vision going forward.
**JORDAN:** Lead to 1 is essentially about personalization at scale using data and AI. The stat that jumped out at me: 8% of patients account for 55% of total healthcare spending. So the whole strategy is built around identifying those complex, high-cost patients earlier and intervening before costs spiral.
**ALEX:** They launched something called HealthSense in September — a tool that connects a patient's health needs, benefits, pharmacy coverage, and claims history so clinical teams get the full picture. It's starting with oncology.
**JORDAN:** And they gave some compelling numbers around this — an integrated cancer patient journey can save $28,000 per person per year. That's not a typo, that's the scale of savings they're talking about for complex care coordination.
**ALEX:** The other big strategic story is the "Signature" model — this is Cigna's attempt to reinvent pharmacy benefits. Instead of the traditional rebate-driven system, it's a fee-based, transparent model.
**JORDAN:** Which matters because, let's be honest, PBMs have taken a lot of regulatory and public heat for opacity. Signature is designed to guarantee patients the lowest available out-of-pocket cost on prescriptions — they're calling it "Price Assure," and it's already saving about 30% on high-cost branded drugs for the rou
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet